Gilead's chief executive calls lenacapavir a once in a decade medicine. The HIV treatment could push Gilead stock further up ...

Lenacapavir has shown high efficacy in managing multidrug-resistant cases, offering hope to patients with limited alternatives. A significant breakthrough in treating the Human Immunodeficiency ...

Local AIDS experts are at odds with the United Nations Programme on HIV/AIDS (UNAIDS) over its claims that AIDS could be ...

GILD has performed well in the past six months, with new drug approvals, positive data readouts and strong quarterly results.

A significant breakthrough in treating the Human Immunodeficiency Virus came recently with the US Federal Drug Administration approving lenacapavir, a new prototype medication. It uses a unique ...

NEW DELHI: In a major step forward in the fight against HIV/AIDS, the US Food and Drug Administration (FDA) has approved Lenacapavir, an injectable HIV drug. This drug protects people for six ...

Human immunodeficiency virus type 1 (HIV-1) targets important cells of our immune system, making infected individuals more ...

In recent years, the investment landscape has seen a significant shift towards socially responsible investing strategies.

Morgan Stanley has upgraded Gilead Sciences (GILD) to overweight from equal weight, citing the company's HIV drug lenacapavir. Read more here.

AbbVie and Gilead are going back to their roots and leaning on their established areas of expertise to set themselves up for ...

A new drug is hugely effective at protecting people from HIV infection and needs to be injected only twice a year.